Tag: Ginkgo BioWorks

Ginkgo Bioworks acquires Zymergen for $300M

Ginkgo Bioworks acquires Zymergen for $300M

August 24, 2022 |

In Massachusetts, Ginkgo Bioworks and the biotechnology company Zymergen (have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization. Under the terms of the agreement, which have been unanimously approved by the boards of directors of both companies, Zymergen […]

Read More

Sumitomo taps Ginkgo Bioworks to replace animal-sourced personal care ingredient

Sumitomo taps Ginkgo Bioworks to replace animal-sourced personal care ingredient

July 18, 2022 |

In Boston, synthetic biology firm Ginkgo Bioworks and Sumitomo Chemical have announced a partnership to identify biobased ingredients for cosmetics and personal care applications.  Sumitomo Chemical will leverage Ginkgo’s codebase and expertise in organism engineering to sustainably produce molecules used in products across a broad range of industries. The target molecule is planned to be […]

Read More

Blood buildings, mushroom mania, lab-grown coffee, ADM, LG Chem, Ginkgo Bioworks news, and more: The Digest’s Top 8 Innovations for the week of September 24th

Blood buildings, mushroom mania, lab-grown coffee, ADM, LG Chem, Ginkgo Bioworks news, and more: The Digest’s Top 8 Innovations for the week of September 24th

September 23, 2021 |

Using astronaut blood to build infrastructure on Mars sounds like part of a sci-fi movie but researchers are working on doing just that thanks to a protein in human blood and an acid in human urine that can bind to Mars dust to create a material strong enough to build infrastructure. In today’s Digest, there’s […]

Read More

Ginkgo Bioworks raises $1.6 billion in NYSE debut

Ginkgo Bioworks raises $1.6 billion in NYSE debut

September 20, 2021 |

In New York, Ginkgo Bioworks began trading on the New York Stock Exchange on Friday, September 17 under the ticker DNA. Debuting at around $15 billion, the SPAC deal raised an estimated $1.6 billion for the Boston-based synthetic biology company.   The company reported $88 million in sales in the first half of 2021, tracking […]

Read More

Ginkgo Bioworks partners with Huue on bio-based dyes

Ginkgo Bioworks partners with Huue on bio-based dyes

August 23, 2021 |

In Massachusetts, Ginkgo Bioworks, Inc. announced a new cell program in partnership with Huue, a biotech startup that’s pioneering sustainable bio-based dyes for the fashion industry and beyond. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp., serves customers across industries seeking to develop new and better products using biology. Huue will […]

Read More

Bolt Threads taps Ginkgo to cut production costs

Bolt Threads taps Ginkgo to cut production costs

August 9, 2021 |

In Boston, newly public synthetic biology firm Ginkgo Bioworks will undertake strain engineering services for Bolt Threads. Under the terms of the agreement, Gingko will use its platform to improve the “sustainability, efficiency and cost-effectiveness” of Bolt Threads’ b-silk protein manufacturing process. b-silk is currently available in premium product lines like Vegamour hair care products—which […]

Read More

Who’s in Hot Water, Cold Water, and Who’s Just Right?: Mitsubishi, Monolith Materials, Codexis, Casdin, LG Chem, Neste, Wells Fargo, EPA, NXTLEVVEL, Elementis, Growth Energy, US National Labs, Ginkgo Bioworks in the news

Who’s in Hot Water, Cold Water, and Who’s Just Right?: Mitsubishi, Monolith Materials, Codexis, Casdin, LG Chem, Neste, Wells Fargo, EPA, NXTLEVVEL, Elementis, Growth Energy, US National Labs, Ginkgo Bioworks in the news

December 2, 2020 |

Who’s in Hot Water? Some of the Usual Suspects get into the usual trouble. We note that EPA missed the 2021 Renewable Volume Obligation deadline, and Growth Energy threatens a lawsuit. Really. We get tired of reporting on the industry having to (almost annually) sue the government to compel compliance to the law. It’s a […]

Read More

Selling Cells – Ginkgo Bioworks Raises $290M, Latest financing brings total to $719M for cell programming

Selling Cells – Ginkgo Bioworks Raises $290M, Latest financing brings total to $719M for cell programming

September 22, 2019 |

Synthetic biology. It sounds like something from a sci-fi movie, or an oxymoron like jumbo shrimp or clearly confused. After all, biology is the study of living organisms. And synthetic means made by chemical synthesis, especially to imitate a natural product. But synthetic biology has real potential to replace costly or unsustainable manufacturing processes and […]

Read More

Genomatica Magica – $90 Million Financing, Commercialized Technologies, Biobased Nylon

Genomatica Magica – $90 Million Financing, Commercialized Technologies, Biobased Nylon

October 21, 2018 |

Bioengineering…it doesn’t sound very magical but it is full of mystery and potential waiting to be unlocked, much like Harry Potter’s character. In the early books and movies, Harry is young, mysterious, smart, and you just know he is capable of something great and destined for amazing things. We feel the same about bioengineering and […]

Read More

Ginkgo’s insane $275M venture haul says it loud: Digital Biology is here

Ginkgo’s insane $275M venture haul says it loud: Digital Biology is here

December 14, 2017 |

Last week we shared with you a framework for a rising technology wave — we called it Digital Biology, the convergence of digital and biological technology waves that is changing genetics from an artisan’s niche into a branch of information technology. More evidence of the power of the Digital Biology wave arrives this week with […]

Read More